Cargando…
Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy
AIMS: As evidenced by scintigraphy imaging, the prevalence of transthyretin (TTR) cardiac amyloidosis in heart failure patients with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) ranges between 13% and 19%. The natural evolution of cardiac amyloidosis begins with the dep...
Autores principales: | Devesa, Ana, Camblor Blasco, Andrea, Pello Lázaro, Ana María, Askari, Elham, Lapeña, Gregoria, Gómez Talavera, Sandra, Taibo Urquía, Mikel, Rodríguez Olleros, Celia, Tuñón, José, Ibáñez, Borja, Aceña, Álvaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318443/ https://www.ncbi.nlm.nih.gov/pubmed/33963812 http://dx.doi.org/10.1002/ehf2.13360 |
Ejemplares similares
-
Prevalence and prognostic value of monoclonal gammopathy in heart failure patients with preserved ejection fraction: A prospective study
por: Devesa, Ana, et al.
Publicado: (2022) -
Multimodality assessments of wild‐type transthyretin cardiac amyloidosis with no ventricular hypertrophy
por: Iwaya, Takuma, et al.
Publicado: (2022) -
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020) -
Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021) -
Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)